Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Novacyt    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Delayed Quote. Delayed Euronext Growth Paris - 11/27 11:35:29 am
8.86 EUR   +5.10%
11/16NOVACYT S.A. : ("Novacyt", the "Company" or the “Group”) R&D Update
BU
10/15NOVACYT S.A. : Acquisition of IT-IS International Ltd
BU
10/15NOVACYT : Acquisition
CO
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Growth Paris
11/23/2020 11/24/2020 11/25/2020 11/26/2020 11/27/2020 Date
8.7(c) 8.01(c) 8.42(c) 8.43(c) 8.86(c) Last
1 358 967 3 795 550 4 308 262 1 011 351 1 338 316 Volume
-2.14% -7.93% +5.12% +0.12% +5.10% Change
More quotes
Financials
Sales 2020 296 M 355 M 355 M
Net income 2020 180 M 216 M 216 M
Net cash position 2020 6,85 M 8,19 M 8,19 M
P/E ratio 2020 3,47x
Yield 2020 -
Sales 2021 338 M 405 M 405 M
Net income 2021 183 M 219 M 219 M
Net Debt 2021 1,20 M 1,44 M 1,44 M
P/E ratio 2021 3,42x
Yield 2021 -
Capitalization 626 M 748 M 748 M
EV / Sales 2020 2,09x
EV / Sales 2021 1,85x
Nbr of Employees 110
Free-Float 99,3%
More Financials
Company
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. Net sales (not including sold divisions) break down by activity as follows: - development of solutions and diagnostic services (51.8%). The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular... 
More about the company
All news about NOVACYT
11/16NOVACYT S.A. : ("Novacyt", the "Company" or the “Group”) R&D Update
BU
10/15NOVACYT S.A. : Acquisition of IT-IS International Ltd
BU
10/15NOVACYT : Acquisition
CO
09/29NOVACYT : Results of annual general meeting
PU
09/29NOVACYT S.A. :  New Contract With UK DHSC for Instrument Platforms and COVID-19 ..
BU
09/29NOVACYT : S.A. ("Novacyt :" or the "Company") Launch of COVID-19 Antibody Test
BU
09/17NOVACYT : Interim Accounts June 2020
PU
09/17NOVACYT : Rapport D'Activitie Semestriel 2020
PU
09/17NOVACYT S.A. ("NOVACYT", THE "COMPAN : Half Year 2020 Results
BU
09/17NOVACYT : Half-year results
CO
09/16NOVACYT : Nomination
CO
09/15NOVACYT : Special Board report on resolutions
PU
09/10NOVACYT : Articles of Association
PU
09/07NOVACYT : The Board special report for EGM
PU
09/07NOVACYT : Form to request documents
PU
More news
News in other languages on NOVACYT
11/16NOVACYT S.A. : (« Novacyt », la « Société » ou le « Groupe ») Avancées en Recher..
11/13SMALL & MID CAPS : les derniers choix des stars de la gestion
10/15EN DIRECT DES MARCHES : Crédit Agricole, Unibail, Lagardère, Publicis, FDJ, Roch..
10/15NOVACYT S.A. :  Acquisition de IT-IS International Ltd
10/13SMALL & MID CAPS : les derniers choix des stars de la gestion
More news
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 14,14 €
Last Close Price 8,86 €
Spread / Highest target 65,1%
Spread / Average Target 59,6%
Spread / Lowest Target 54,1%
EPS Revisions
Managers
NameTitle
Graham David Mullis Chief Executive Officer & Executive Director
James Christopher Wakefield Chairman
Lisa Henriet Director-Group Operations
Anthony Dyer CFO, Secretary & Executive Director
Jean-Pierre Crinelli Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVACYT5,142.60%748
GILEAD SCIENCES, INC.-7.62%74 585
VERTEX PHARMACEUTICALS3.54%56 714
REGENERON PHARMACEUTICALS36.90%53 649
LONZA GROUP AG55.15%44 901
MODERNA, INC.549.44%43 204